Mbii) (mbi) leads the movement to a more sustainable world through the discovery, development and promotion of biological products for pest management and plant health. This compares to loss of $0.03 per share a year ago. 10, 2021 — marrone bio innovations, inc.
Marrone Bio Innovations Venerate CG 2.5 Gallon
Mbii) (mbi) leads the movement to a more sustainable world through the discovery, development and promotion of biological products for pest management and plant health.
Its products include grandevo insecticide, majestene nematicide, regalia fungicide, stargus fungicide, venerate insecticide, amplitude fungicide, regalia rx plant health, zelto.
Mbii), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the third quarter ended september 30, 2021. Discovers, develops, produces, and promotes biological products for pest management, plant nutrition, and. Marrone bio innovations currently has a consensus price target of $2.08, indicating a potential upside of 93.93%. Marrone bio to sell for $236 million to argentinian company bioceres.
Argentinian company bioceres crop solutions corp.
Mbii).today, shares of mbii stock have surged nearly 50%. (mbii) came out with a quarterly loss of $0.03 per share in line with the zacks consensus estimate. Over 12 months, marrone bio innovations reported revenue of us$41m, which is a gain of 10%, although it did not report any earnings before interest and tax. Marrone bio to sell for $236 million to argentinian company bioceres.
Mbii) (mbi) leads the movement to a more sustainable world through the discovery, development and promotion of biological products for pest management and plant health.
Our effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health, and. Given marrone bio innovations' higher probable upside, research analysts plainly believe marrone bio innovations is more favorable than nutrien. Nutrien has a consensus price target of $98.00, indicating a potential downside of 4.67%. According to the issued ratings of 4 analysts in the last year, the consensus rating for marrone bio innovations stock is buy based on the current 1 hold rating and 3 buy ratings for mbii.
